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10Supplemental material is available online.Atrial fibrillation (AF) is present in 1% to 2% of the general
population, and its prevalence has been predicted to
increase more than fivefold within the next 40 years.1,2
Patients with AF are at least five times more likely to
have a stroke than patients without AF.3 Approximately
90% of all strokes are ischemic, and 15% to 20% of all
ischemic strokes are associated with AF.4-6 The left atrial
appendage (LAA) is the site of more than 90% of
detected thrombi in patients with AF.7 As a result of
the recent development of potentially safer and more
effective percutaneous devices8-10 and minimally invasive
surgical techniques11,12 for closing the LAA, interest is
renewed in the potential for using these mechanical
approaches to decrease the incidence of stroke in patients
with AF.13,14
EFFECT OF LAA CLOSURE ON THE INCIDENCE
OF STROKE
Previous studies designed to determine the effect of
closure of the LAA on the incidence of stroke have
yielded mixed results.15,16 One reason is that patients
with AF frequently have associated comorbidities that
could themselves be the source of ischemic strokes
(eg, intracerebral vascular disease, carotid artery stenosis,
atherosclerosis of the proximal aorta, valvular heart
disease, and left heart failure).
The first large, prospective, randomized trial to evaluate
the effect of LAA closure on the subsequent incidence of
stroke was reported in 2005 and included patients undergo-
ing coronary artery bypass grafting (CABG).15 The Left
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18 The Journal of Thoracic and Cardiovascular SurLAA was closed by 1 of 2 methods, epicardial suture or
epicardial stapling. However, complete closure was attained
with the suture technique in only 43% of patients, with
the predominant failure mode a residual or recurrent
connection between the LAA and the left atrium. Stapling
was successful in only 72% of patients, and the other
28% were considered to have treatment failures because
of a persistent remnant at the base of the LAA that was
greater than 1 cm in length. Largely because of this inability
to attain permanent LAA closure, the Left Atrial
Appendage Occlusion Study did not show a significant
reduction in the incidence of stroke between the study
(occlusion) and control groups. Further complicating
the question of whether closure of the LAA should be
attempted was the observation that incomplete closure is
often more dangerous than no closure at all.15,16
Despite the technical inadequacies and equivocal results
of such surgical studies, the ‘‘American College of
Cardiology/American Heart Association guidelines for the
management of patients with valvular heart disease’’
recommend amputation of the LAA at mitral valve surgery
to reduce the incidence of subsequent thromboembolic
events.17 Moreover, the ‘‘American Heart Association/
American College of Cardiology/European Society of
Cardiology guidelines for the management of patients
with atrial fibrillation’’ have recommended surgical LAA
closure in cardiac surgical patients ‘‘.who are at risk of
developing postoperative AF.’’7 These consensus recom-
mendations for relatively small, highly selected, groups of
patients are clearly based on recognition of the importance
of the LAA in the genesis of strokes associated with AF.
However, they beg the question of whether similar
recommendations should be made to close the LAA in the
millions of patients in the general population who have
AF. Catheter ablation has been performed for AF for nearly
2 decades and, despite 2- to 5-year recurrence rates of more
than 70% after a single catheter ablation,18-20 concomitant
closure of the LAA is not a routine part of these procedures,
largely because the new catheter-based closure devices
were not yet approved by the Food and Drug Administration
(FDA). In addition, many of the contemporary minimally
invasive surgical procedures for AF also do not routinely
include closure of the LAA.21
Our experience with the surgical treatment of AF
suggests that removal or proper closure of the LAA at
surgery reduces the risk of early perioperative strokes
dramatically and nearly eliminates the risk of subsequentgery c November 2013
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Abbreviations and Acronyms
AF ¼ atrial fibrillation
CABG ¼ coronary artery bypass grafting
FDA ¼ Food and Drug Administration
LA ¼ left atrial
LAA ¼ left atrial appendage
RA ¼ right atrial
Cox Editoriallong-term stroke.22 The incidence of perioperative stroke
has been 3.2% after CABG, 2.8% after valve surgery,
and 6.7% after CABG plus valve surgery.23 However, in
our experience when a maze procedure for AF was
performed either as a ‘‘stand-alone’’ procedure or was
added to these other surgical operations as a ‘‘concomitant’’
procedure, the incidence of perioperative stroke decreased
to less than 1%.24 This observation was particularly
surprising because nearly 20% of the patients in our series
had a history of at least 1 systemic thromboembolic event
before their surgery, putting them at an even greater risk
of perioperative stroke.
One might suspect that because of the concomitant maze
procedure those patients did not have perioperative AF and,
therefore, fewer perioperative strokes occurred for that
reason. However, 37% of those patients had perioperative
AF. Only patients with a history of previous stroke or
transient ischemic attack and those with mechanical valve
prostheses were anticoagulated with warfarin in the
immediate postoperative period. The remaining patients,
representing a substantial majority, received no early post-
operative anticoagulation, although they were routinely
instructed to take aspirin. Thus, the only plausible explana-
tion for the dramatic reduction in the expected perioperative
stroke rate in such high-risk patients was that the LAAwas
either removed or properly closed in every patient as a part
of the maze procedure.
In the original ‘‘cut-and-sew’’ maze patients, the excised
LAAs were immediately examined for thrombi at surgery
by opening them longitudinally from the base to the tip.
When the original ‘‘cut-and-sew’’ maze procedure was
supplanted by the minimally invasive ‘‘cryosurgical maze
procedure’’ in the mid-1990s,25 the LAA was no longer
excised but instead was inverted into the left atrial cavity,
directly examined for thrombi, returned to its normal
position, and closed endocardially. This direct visual
examination of the LAA in 360 patients, 19% of whom
had previously experienced either a stroke or transient
ischemic attack, revealed small thrombi in the trabeculated
LAA in only 2 patients, both of whom had experienced
multiple thromboembolic episodes within the week before
undergoing an emergency maze procedure for the recurrent
strokes. No thrombi were found elsewhere inside the leftThe Journal of Thoracic and Caratrium, pulmonary veins, or left ventricle in any of the
360 patients.
During the 15 years after the maze procedure and surgi-
cal removal or endocardial suture closure of the LAA,
only 1 patient experienced an ischemic stroke.26 Of those
patients, 65% had received no long-term anticoagulation,
and the only indication for long-term anticoagulation in
the remaining 35% was the presence of a mechanical
valve prosthesis, AF recurrence, or the preference of the
referring physician. It has been suggested that the dramatic
reduction in the expected long-term stroke rate in these
high-risk patients was because 94% of them were still
free of AF after 15 years.27 However, because of the dra-
matic decrease in the incidence of perioperative strokes in
the same patients, a more plausible explanation is that the
LAA had either been removed or properly closed in all the
patients.PATHOPHYSIOLOGY OF LEFT HEART
THROMBOSIS IN AF
The 3 factors constituting ‘‘Virchow’s triad’’ respon-
sible for spontaneous intravascular thrombosis are hyper-
coagulability, endothelial injury, and stasis of blood
flow.28 A recent study by Lim et al29 documented that
AF itself, as well as prolonged rapid heart rates, can
induce hypercoagulability that is more severe within the
atria than in the peripheral circulation. Although their
elegant study has provided an important insight into why
patients with AF have an increased incidence of stroke,
it did not explain why a difference exists between the inci-
dence of right-heart and left-heart thromboembolism in
patients with AF. Patients with hypercoagulation syn-
dromes have the same hypercoagulability problem with
blood inside the fibrillating right atrium as they do with
blood inside the fibrillating left atrium. Thus, if hyperco-
agulability were the primary culprit in thromboembolism
associated with AF, pulmonary embolism from the right
heart should be as common as systemic embolism from
the left heart.
The study by Lim et al29 also presented a case for
AF-induced endothelial injury in both atria as a factor in
promoting atrial thrombogenesis. Atrial stretching and
fibrosis, with potential endothelial injury, would be
expected to be more prominent in the left atrium than in
the right atrium in patients with AF because many of
them have left-sided heart problems such as hypertension,
ischemic heart disease, and mitral and/or aortic valve
disease. Thus, it is possible that a disparity in endothelial
injury could be one reason thromboemboli originate more
commonly in the left heart. However, this notion is only
theoretical, because their study does not differentiate
between endothelial injury in the right and left atria. Indiovascular Surgery c Volume 146, Number 5 1019
FIGURE 1. Anatomy of the right atrium showing the relatively large size
of the orifice of the right atrial appendage in relation to its depth.
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Editorial Coxany event, differential right and left atrial endothelial injury
is likely to be less important than the marked disparity in the
degree of stasis in the right and left atria during AF.
Several reasons exist for the difference in right and left
heart stasis during AF. Although both the right atrial (RA)
appendage and LAA are heavily trabeculated in their distal
portions,30 the orifice of the RA appendage is relatively
broad in relation to its depth (Figure 1), and the wide orifice
of the RA appendage is positioned adjacent to the predom-
inant path of flow as blood courses from the superior andFIGURE 2. Anatomy of the left atrium showing the relatively small size
of the orifice of the left atrial appendage (LAA) in relation to its depth.
LSPV, Left superior pulmonary vein; SVC, superior vena cava; LPA, left
pulmonary artery; RSPV, right superior pulmonary vein; PT, pulmonary
trunk; RPA, right pulmonary artery; LA, left atrium; MV, mitral valve;
LV, left ventricle; IVC, inferior vena cava.
1020 The Journal of Thoracic and Cardiovascular Surinferior vena cavae to the tricuspid valve. Thus, the interior
of the RA appendage is continuously ‘‘washed’’ by the
blood stream, even during AF. In contrast, the orifice of
the LAA is quite small compared with its depth30
(Figure 2), and the blood from the nearby pulmonary veins
flows more directly into the orifice of the mitral valve. Flow
from the adjacent left pulmonary veins is actually directed
away from the LAA orifice toward the mitral valve. Thus,
the LAA, especially in its distal trabeculated portions, is
not ‘‘washed’’ as thoroughly by the predominant blood
stream during AF as is the RA appendage. Therefore, the
degree of stasis in the LAA is substantially worse than
that in the RA appendage at least in part because of differ-
ences in the anatomy.
The generally accepted notion of the pathophysiology of
thromboembolism associated with AF is that a fixed
thrombus forms in the left heart and then either the entire
thrombus or a portion of it breaks off and embolizes
systemically.31 However, our unique premortem observa-
tions of the inside of the LAA in the maze patients have
suggested an alternative picture of the predominant
pathophysiology of thromboembolism in AF. In this
alternative scenario, severely static blood in the LAA
congeals into a free-floating thrombus and, once formed,
quickly embolizes to the systemic circulation, leaving no
trace of its former, rather fleeting, existence. This view is
most consistent with the absence of thrombi noted on
premortem examination of the left heart and LAA in the
vast majority of patients known to have had thromboem-
bolic events associated with AF.
The specific site of thrombus formation within the LAA
is important clinically, because it determines the level at
which the appendage can be safely excluded. Some inves-
tigators have emphasized the necessity for closure or
resection as near as possible to the anatomic ‘‘base’’ or
‘‘neck’’ of the LAA, suggesting that if a small pouch or
diverticulum remains after closure, it might actually in-
crease the likelihood of thrombus formation.15,32
However, virtually all LAAs are anatomically consistent
in that the proximal 1 to 2 cm of the LAA is smooth
and devoid of trabeculae.30 A small residual pouch of
less than 1 cm at the base of a closed LAA using the
newer closure devices has had no effect on the subsequent
development of thromboembolism from that pouch
remnant.10,15 Clearly, a much greater potential problem
with contemporary closure devices is that some of them
leave a residual connection between the body of the left
atrium and the LAA itself.
POTENTIAL CONSEQUENCES OF LAA CLOSURE
OR REMOVAL
Arrhythmogenicity
Recent studies have shown that the LAA can be the site of
triggers that can induce episodes of paroxysmal AF and ofgery c November 2013
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Cox Editorialre-entrant drivers that participate in the maintenance of
persistent AF.33,34 Therefore, exclusion of the LAA
electrically can result in an improvement in the results of
interventional catheter and surgical procedures for AF.
LATransport Function
During sinus rhythm, the mechanical activity of a normal
left atrium can be divided into 3 phases: a reservoir phase
(expansion) during ventricular systole, a conduit phase
during early ventricular diastole, and an active contractile
phase during late ventricular diastole.35 Because transport
function of the LAA itself can be differentiated from that
of the left atrium, a theoretical possibility exists that lossFIGURE 3. Postoperative electrograms of the right atrium, left atrium (L.
simultaneous monitoring of the cardiac output (aortic flow), systemic arterial b
pulmonary artery (P.A.) pressure. In the control tracings, the right and left atria
30 ms to simulate the exact activation pattern that existed preoperatively during
discontinued (Silent L.A.). No alterations in normal atrioventricular conduction f
afterload, or cardiac output. The left atrium is then paced at a rate of 300 pulses/m
the right atrium or in the preload, afterload, or cardiac output. (Reproduced w
ECG, electrocardiogram.
The Journal of Thoracic and Carof the LAA’s contribution to 1 or more of these 3 phases
could result in a decrease in forward cardiac output.36
However, this concern assumes that LA function equates
to bi-atrial function, an assumption that is incorrect.
Atrioventricular synchrony is generally accepted to
increase the cardiac output roughly 20% compared with
the cardiac output during AF or ventricular pacing.
However, this improvement in cardiac output occurs only
when both atria are contracting in synchrony with their
respective ventricles. In 1980, we described a procedure
in which the entire left atrium, including the LAA, was
surgically isolated, both electrically and mechanically,
from the remainder of the heart.37 This so-called LAA.), right ventricle, and lead II electrocardiogram are recorded during
lood pressure (B.P.), left ventricular end-diastolic pressure (LVEDP), and
are both being paced, but the pacing stimulus to the left atrium is delayed
normal sinus rhythm. The pacing stimulus to the left atrium is then abruptly
rom the right atrium occur, yet there is no change in left ventricular preload,
in (L.A. SVT),with no alteration in normal atrioventricular conduction from
ith permission from Williams et al.37) SVT, Supraventricular tachycardia;
diovascular Surgery c Volume 146, Number 5 1021
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intraoperative mapping techniques were available and was
designed to confine automatic LA tachycardias to the left
atrium, thereby freeing the sinoatrial node to drive the right
atrium and both ventricles. Although this was strictly an
antiarrhythmia operation, electromechanical isolation of
the left atrium provided a unique opportunity to evaluate
the contribution of LA contraction alone to forward cardiac
output. Our experimental studies demonstrated that as long
as synchronous activation is present of the right atrium and
right ventricle, synchronous LA contraction has no effect on
the preload, afterload, or forward cardiac output of the left
ventricle (Figure 3). As long as the right heart is capable of
delivering normal cardiac output through the pulmonary
vasculature to the left atrium, the left ventricle will
accept that output and deliver it to the systemic circulation,
regardless of the status of LA function or that of its
appendage. Because the mechanical activity of the
entire left atrium, including the LAA, has no discernable
independent effect on forward cardiac output, closure of
only the LAA would likewise not have a significant
independent effect on cardiac hemodynamics.
These observations emphasize that the importance of
atrioventricular synchrony is the timing, not the force, of
the atrial contraction in late ventricular diastole. A useful
analogy is to think of a child on a backyard swing. If the
adult swinging the child were to stop the child at the apogee
of each swing cycle and then forcefully push the child every
swing cycle, a great deal of energy would have to be
expended to keep the child swinging. However, experience
tells us that once the child is already swinging, only a light
‘‘tap’’ on the child’s back at exactly the right time in
the swing cycle will keep the child swinging indefinitely.
The same dynamic principle is at work between the
atria and their respective ventricles during atrioventricular
synchrony, and it appears to be the primary mechanism
that results in what we perceive as being a forceful atrialFIGURE 4. Disappearance of the left atrial appendage (LAA) after applica
1022 The Journal of Thoracic and Cardiovascular Sur‘‘contraction.’’ During atrioventricular synchrony, the
atrium provides a light ‘‘tap’’ to the already moving atrial
blood pool at precisely the right time, thereby enhancing
the efficiency of ventricular filling during ventricular
diastole. Rather than using the term ‘‘atrial kick,’’ perhaps
it would be more accurate to refer to the participation of
the atrium as an ‘‘atrial tap.’’
Regulation of Fluid Balance
The LAA has stretch receptors that can partially regulate
thirst and other endocrine-like cells that help to regulate
fluid balance by producing atrial natriuretic peptide.38
Removal of the LAA temporarily reduces the circulating
levels of atrial natriuretic peptide, sometimes resulting in
excessive fluid retention in the immediate postoperative
period. This was a common early complication of the
original cut-and-sew maze procedure in which both the
LAA and RA appendage were excised.39 Subsequent
iterations of the maze procedure retained the RA
appendage,40 which also produces atrial natriuretic
peptide41 and, therefore, ameliorated this complication of
LAA removal.
CONTEMPORARYMETHODS FOR CLOSING THE
LAA
Surgical Techniques
The previous difficulty in attaining complete appendage
closure has largely been overcome by the recent
introduction of external clips that can be positioned quickly
and easily near the base of the LAA during surgery.
The device most commonly used is the AtriClip (Atricure,
Inc, West Chester, Ohio), which is designed so that the
inherent expansive force exerted by the nitinol is directed
centrally from both sides of the clip to apply a constant
dynamic pressure to the base of the LAA, thereby keeping
it closed permanently.12 This external clip not only closes
the LAA effectively, but it also interrupts the myocardialtion of the external surgical AtriClip. (Modified from Ailawadi et al.12)
gery c November 2013
FIGURE 5. Disappearance of the left atrial appendage (LAA) after application of the external percutaneous Lariat.
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Cox Editorialblood supply of the appendage itself, resulting in its gradual
disappearance (Figure 4). In the multicenter FDA-approved
Atricure Exclusion of the LAA in Patients Undergoing
Concomitant Cardiac Surgery (EXCLUDE) trial, the LAA
was closed successfully with the AtriClip device in
98.4% of patients, with no device-related mortality.12
Percutaneous Nonsurgical Techniques
The safety and efficacy of the Watchman device (Boston
Scientific, Natick, Mass) for LAA occlusion were compared
with those of standard oral anticoagulation therapy for the
reduction of stroke in the Percutaneous Closure of the
Left Atrial Appendage Versus Warfarin Therapy for
Prevention of Stroke in Patients With Atrial Fibrillation
(PROTECT-AF) trial.8,42 The latest follow-up data of that
trial’s 800 patients showed for the first time that the
Watchman is superior to warfarin for the primary efficacy
endpoint and equivalent to oral anticoagulation for the
primary safety endpoint.43 The safety and efficacy of the
Amplatzer plug (St Jude Medical Inc, St. Paul, Minn) for
LA closure appear to be similar to those of the
Watchman.9,44 However, both devices have the same
major disadvantage in that a relatively large foreign body
remains permanently inside the left atrium.
The Lariat system (SentreHEART Inc, Palo Alto, Calif)
precludes the problem of a permanent intracardiac foreign
body because the LAA is closed with a single ligature
around the outside of the LAA.10 One disadvantage of the
Lariat system is that it requires a ‘‘dry stick’’ of the
pericardium for the introduction of the pericardial catheter,
although this has not proved to be a significant deterrent to
its use by nonsurgeons. The Lariat system also requires an
endocardial catheter and incorporates magnets on both the
endocardial balloon catheter and the pericardial catheter
to accomplish optimal placement of the epicardial ligature
near the base of the LAA. Because different operators are
incapable of tightening a suture around the appendage
with the same degree of pressure, the Lariat systemThe Journal of Thoracic and Carincludes the TenSURE tightening device, which always
applies the same tightening pressure, thus eliminating
individual operator variability. Soft tissue, such as the
LAA, can remodel around the tightened ligature soon after
placement. Therefore a 5-minute ‘‘waiting period’’ after the
initial ligature tightening must be allowed before the
ligature undergoes its final tightening with the TenSURE
device. The Lariat system has 2 other features that
offer advantages over the Watchman and Amplatzer
devices: (1) the status of LAA closure can be monitored
continuously and in real time by the operator during the
procedure using echocardiography and/or angiography,
and (2) the device can be released for better positioning
during the procedure if necessary.
In the Permanent Ligation Approximation Closure
Exclusion (PLACE) II study of the Lariat system, imaging
techniques were used to evaluate the status of the LAA
before and during the procedure and at 30 days, 90 days,
and 1 year after the procedure.10 Despite a more rigid
definition of ‘‘successful closure’’ than was used for the
Watchman, the Lariat system attained complete closure
by transesophageal echocardiography at 1 and 3 months
after ligation. Of the patients undergoing transesophageal
echocardiography 1 year later, 98% had complete closure
of the LAA, including the patients with previous leaks at
1 and/or 3 months. Just as with the surgical AtriClip, the
catheter-based Lariat system, with its epicardial ligature,
interrupts the myocardial blood supply of the LAA,
resulting in its gradual disappearance over time (Figure 5).
PATIENTS WHO SHOULD BE CONSIDERED FOR
MECHANICAL LAA CLOSURE
Because the Watchman device has now been shown to be
superior in efficacy and equivalent in safety to oral
anticoagulation, it is reasonable to assume that the
Amplatzer plug, with a similar risk/benefit profile, would
offer similar results compared with oral anticoagulation,
although that has not yet been proved. The earlydiovascular Surgery c Volume 146, Number 5 1023
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systems suggest that interventional cardiologists might
soon be able to close the LAA with an approved
percutaneous device that is safer and more effective than
oral anticoagulant therapy for the prevention of strokes.
Should that potential be realized, not only with the
percutaneous devices, but also with the surgical AtriClip,
the most pressing issue would be to identify those patients
who might benefit most from mechanical closure of the
LAA as prophylaxis for ischemic strokes.
Patients With AF Who Cannot Take Anticoagulants
Clearly, patients with AF who cannot take anticoagulants
should be considered for mechanical closure of the LAA.
The demonstration of superiority of the Watchman device
compared with oral anticoagulation therapy also raises the
question of whether mechanical closure of the LAA should
be considered even for patients who can take oral anticoa-
gulation. Although oral anticoagulation clearly decreases
the incidence of ischemic strokes in patients with AF,45,46
unlike the mechanical devices, it also increases the
incidence of hemorrhagic strokes, which are more lethal
than ischemic strokes.47,48 Moreover, a major problem
with oral anticoagulation therapy is that only about one
half of all patients who are candidates for
oral anticoagulant therapy are actually anticoagulated
adequately, either because of difficulties in maintaining
patients within the therapeutic international normalized
ratio range or patient noncompliance.49,50 This
observation suggests that any patient considered for oral
anticoagulation should also be considered for mechanical
closure of the LAA. Exceptions would include only those
patients who will be strictly compliant with oral warfarin
therapy and who can be maintained reliably within the
therapeutic international normalized ratio range. An
important development that could modify this more
aggressive approach to mechanical closure is the recent
introduction of newer anticoagulants such as dabigatran,
rivaroxaban, and apixaban, all of which have shown
noninferiority or superiority to warfarin in preventing
ischemic stroke.51 These new agents require no therapeutic
drug monitoring; however, patient adherence, lack of a
reversal agent, cost, and other safety concerns remain
reasons for caution. Furthermore, older adults have
experienced more adverse effects from these agents.
Patients Undergoing Catheter Ablation for AF
Electrophysiologists performing catheter ablation for AF
have rarely used these LAA occluding devices, primarily
because of current FDA restrictions. However, the prom-
ising risk/benefit ratio of the percutaneous catheter-based
systems should offer interventional electrophysiologists
the future option of closing the LAA in patients undergoing
catheter ablation for AF. Moreover, LAA closure might1024 The Journal of Thoracic and Cardiovascular Surimprove catheter ablation outcomes, such as was suggested
by the recent demonstration that LAA ligation appears to
decrease the AF burden.33,34,52 Because the percutaneous
LARIAT system and surgical AtriClip are the only
mechanical devices that are capable of causing complete
electromechanical isolation of the myocardium of the
LAA by devascularization, they would seem to be the
ones most likely to improve catheter ablation outcomes
for AF.
Patients With AF Not Considered Candidates for
Interventional Therapy
Patients with AF who are not candidates for either
catheter ablation or surgery represent the largest group at
risk of stroke due to AF, numbering in the millions in the
United States alone. The best estimates from industry
sources have suggested that some 311,000 patients
underwent catheter ablation for AF in 2012, representing
only 2.1% of all patients with AF.53 Many, if not most,
of these patients have nonparoxysmal (persistent or
long-standing persistent) AF and are not considered good
candidates for catheter ablation, and other patients have
too many comorbidities or are too infirm to be candidates
for hours-long catheter ablation procedures or invasive
surgical procedures. One future option for these patients
is to ablate the His bundle, insert a permanent pacemaker,
and close the LAA, all of which would be attainable without
surgery.54 In patients resistant to drug therapy and not
candidates for interventional therapy, this ‘‘ablate, pace,
and occlude’’ approach might prove the best option, even
though it leaves the patients in AF and requires a permanent
pacemaker. In such patients, it is prudent to remember that
AF itself rarely kills patients, it is the strokes due to AF that
kill patients.
Patients Undergoing Cardiac SurgeryWith a History
of AF
The vast majority of adult cardiac surgery falls into 3
categories: CABG, aortic valve surgery, and mitral valve
surgery. It is impossible to determine exactly how many
of these patients enter the operating room annually in the
United States with concomitant AF, but estimates have
ranged from 60,000 to 100,000.55,56 Using a median
number of 80,000 patients, no more than 25,000 of them
currently undergo a concomitant procedure for their AF,
with a success rate of approximately 80%.57,58 Ignoring
AF in more than two thirds of these patients is difficult to
justify knowing that the benefits of ablating AF with a
concomitant AF surgical procedure include an improved
quality of life,59 less perioperative morbidity,60 a lower
incidence of perioperative thromboembolic events and
valve morbidity,61,62 less tricuspid insufficiency,63,64 and
improved long-term survival.62,65,66 At the 2010 Annual
Meeting of the American Association for Thoracicgery c November 2013
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Cox EditorialSurgery, an independent survey of the attendees was
conducted by questionnaire to determine the reasons AF
is ignored by surgeons in more than two thirds of
patients with concomitant AF (unpublished data). The
overwhelming reason given was that surgeons were
concerned about increasing the operative risk by adding
additional surgery for AF to the primary coronary, aortic,
or mitral procedure. Ad et al67 subsequently reported that
adding the maze-III procedure to CABG and aortic valve
surgery did not increase the morbidity or mortality of the
procedures. In fact, their results suggested that the patients
who had their AF addressed with concomitant surgery
actually did better than those in whom the AF was
ignored.67 Despite these studies documenting the safety
and efficacy of treating both the primary cardiac problem
and the concomitant AF, if inexperienced surgeons continue
to be reluctant to treat the concomitant AF, they should at
least be willing to add a simple 5-minute procedure to close
the LAA.
All Patients Undergoing Cardiac Surgery
Perioperative AF increases the risk of perioperative
stroke, prolongs hospitalization and intensive care unit
stays, and increases the 30-day operative mortality after
cardiac surgery.68,69 The American Heart Association/
American College of Cardiology/European Society of
Cardiology consensus recommendation for closure of the
LAA in cardiac surgical patients at high risk of
developing perioperative AF is complicated by the fact
that approximately two thirds of all patients undergoing
cardiac surgery will not develop perioperative AF,
regardless of the procedure performed,70 and it is impos-
sible to identify the remaining one third preoperatively.
Thus, this consensus recommendation is not particularly
helpful to the practicing cardiac surgeon. Because
epicardial suture closure of the LAA by surgeons is fraught
with both short- and long-term failure, and because of the
current safety and efficacy of closing the LAA with an
external clip, why not close the LAA in all patients
undergoing cardiac surgery? Clearly, the greatest deterrent
to such a suggestion is the added cost of the LAA clips.
However, the cost of these devices is miniscule compared
with the added costs attendant to perioperative
strokes.68,69,71
Patients With Subclinical AF
All these patients had a clinical diagnosis of AF, except
those in the last group and, therefore, are known to be at a
fivefold risk of having an ischemic stroke. A recent study
addressed patients with subclinical AF (tachyarrhythmias
>190 beats/min for>6 minutes) discovered by previously
implanted pacemakers or defibrillators with monitoring
capabilities.72 The study included 2580 patients aged 65
years or older with hypertension and no history of AFThe Journal of Thoracic and Carwho were followed up for a mean of 2.5 years. The risk
of stroke or systemic embolism associated with subclinical
AF was 13%. This ominous, but important, study raises the
question of whether such high-risk patients should receive
prophylactic oral anticoagulation therapy or mechanical
LAA closure, despite having no history of AF.
CONCLUSIONS
The most debilitating and life-threatening complication
of AF is stroke. Most strokes due to AF have their origin
in the trabeculated portions of the LA appendage. Oral
anticoagulation therapy for the prophylaxis of strokes
associated with AF has been less than optimal and difficult
to manage clinically. Several safe and effective percuta-
neous and surgical methods for closing the LAA have
now been developed and will hopefully be fully approved
by the FDA in the near future. These new devices and
techniques have the capability of drastically reducing the
number of strokes associated with AF. The LAA has been
accurately termed ‘‘our most lethal human attachment,’’73
and we are now obliged to consider its mechanical closure
in a larger spectrum of the population. Routine mechanical
closure of the LAA in a wider number and variety of
patients would likely have a greater effect on the morbidity
and mortality of the general population than any other
single therapy for any other clinical problem within our
grasp today. It is time for us to act on that potential without
further delay.
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